Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
6
×
Tags
boston blog main
6
×
boston top stories
cancer
6
×
indiana blog main
indiana top stories
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
6
×
biotech
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
fda
national
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
clinical trials
drugs
europe blog main
europe top stories
roche
startups
blueprint medicines
deals
eli lilly
genentech
investing
What
fda
6
×
drug
bio
cancer
roundup
approved
genetic
medicine
medicines
new
activity
address
ahead
approval
approvals
approves
asco
biogen
blueprint
branded
carries
certain
choices
clamped
commissioner
companies
consumers
costly
counterweight
covid
deeper
delays
designed
developing
digital
disease
dna
drugs
economic
eisai
Language
unset
Current search:
photo
×
fda
×
" san francisco top stories "
×
" boston blog main "
×
cancer
×
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks
@xconomy.com
5 years ago
Bio Roundup: Generic Drugs Graft, ASCO Ahead, ElevateBio Rises & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues